Title
Category
Credits
Event date
Cost
Hidradenitis Suppurativa Clinician-Patient Summit
  • LivDerm
  • TME
  • 2.00 ACPE Pharmacy
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC
  • 2.00 Participation
$0.00
Hidradenitis suppurativa has significant impacts on patients’ quality of life, however, it remains underdiagnosed, misdiagnosed, or incorrectly treated.  Until recently, there was a scarcity of evidence about long-term management strategies and no evidence-based consensus guidelines.  The updated North American guidelines, as well as the growing armamentarium of agents in advanced clinical development, provide additional guidance for optimizing diagnosis and treatment of HS patients.  However, questions still remain about how to best individualize therapy and work as a partner with patients
Advances in Managing Eosinophilic Esophagitis: Tips for the Practicing Clinician
  • TME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Eosinophilic esophagitis (EoE), a chronic, debilitating illness that is mediated via cells of the immune system (eosinophils) eliciting T-helper 2 (Th2) cell mediated inflammation, affects several people globally and imparts significant impact on the quality of life (QoL) of the affected patient population. Advanced disease can lead to esophageal tissue remodeling and dysfunction, underscoring the importance of prompt diagnosis. However, evidence suggests delayed diagnosis for EoE occurs frequently.
AhR Agonists for Psoriasis: A Novel Mechanism for Treatment of PsO
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Psoriasis is a difficult disease to manage due to a variety of factors including fluctuations in disease severity, limited treatment options, and a limited understanding of the pathogenesis of disease. Recently, the first new topical for PsO since 1997 was approved for adults with plaque PsO. This agent is a novel, steroid-free aryl hydrocarbon receptor (AhR) agonist with no restrictions for duration, location, or extent of use.
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
  • CMHC
  • TME
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. MASH represents a metabolic-driven array of multi-organ pathology that intersects with obesity, prediabetes, type 2 diabetes, and cardiovascular ailments. Many agents are currently in development for treatment of MASH, including glucagon-like peptide-1 receptor agonists (GLP1-Ras).